2-(4-aminobutoxy)-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide | 1420290-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-aminobutoxy)-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide
• 英文别名: HJC0431
• CAS: 1420290-90-9
• 化学式: C₁₇H₁₇Cl₂N₃O₄
• 分子量: 398.246
• InChiKey: FQAQPTVYOLIJBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  氯硝柳胺 在 偶氮二甲酸二异丙酯 、 三苯基膦 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.0h， 生成 2-(4-aminobutoxy)-5-chloro-N-(2-chloro-4-nitrophenyl)benzamide
  参考文献：
  名称：

  Discovery of O-Alkylamino-Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents

  摘要：

  Niclosamide has been identified to potently inhibit the activation, nuclear translocation, and transactivation of STAT3. Nevertheless, the poor aqueous solubility and bioavailability of niclosamide have hindered its further clinical development for cancer therapy. To discover new molecules with enhanced druglike properties, a series of novel O-alkylamino-tethered derivatives of niclosamide have been designed, synthesized, and biologically evaluated. Among them, compound 11 (HJC0152) has been demonstrated to significantly suppress MDA-MB-231 xenograft tumor growth in vivo (ip and po), indicating its great potential as efficacious and orally bioavailable therapeutics for human cancer.

  DOI：

  10.1021/ml3003082

文献信息

• [EN] STAT3 INHIBITOR<br/>[FR] INHIBITEUR DE STAT3
  申请人：UNIV TEXAS

  公开号：WO2014113467A1

  公开（公告）日：2014-07-24

  Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

  提供了STAT3抑制剂和治疗炎症或过度增殖疾病（例如癌症）的方法。在某些方面，化合物可用于治疗乳腺癌、头颈癌、肺癌、前列腺癌或胰腺癌。
• COMPOUNDS AND METHODS FOR INHIBITING VIRAL REPLICATION AND METHODS OF TREATING AND PREVENTING FLAVIVIRAL INFECTIONS
  申请人：Health Research, Inc.

  公开号：US20220024884A1

  公开（公告）日：2022-01-27

  The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

  本公开涉及公式（I）的化合物或其药用可接受盐。本公开进一步涉及抑制病毒复制的方法，包括将感染病毒的一个或多个细胞与公式（I）的化合物或其药用可接受盐的有效量接触，其中该病毒包括黄病毒。还公开了一种治疗和/或预防黄病毒感染和/或由黄病毒感染引起的病况的方法，包括在有效条件下给予公式（I）的化合物或其药用可接受盐的有效量，以治疗和/或预防黄病毒感染和/或由黄病毒感染引起的病况。
• STAT3 INHIBITOR
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20150361031A1

  公开（公告）日：2015-12-17

  Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

  提供了STAT3抑制剂和治疗炎症或过度增殖疾病（例如癌症）的方法。在某些方面，化合物可用于治疗乳腺癌、头颈癌、肺癌、前列腺癌或胰腺癌。
• Discovery of niclosamide and its O-alkylamino-tethered derivatives as potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates
  作者：Jimin Xu、María Eugenia Pachón-Ibáñez、Tania Cebrero-Cangueiro、Haiying Chen、Javier Sánchez-Céspedes、Jia Zhou

  DOI：10.1016/j.bmcl.2019.03.032

  日期：2019.6

  Carbapenemase-producing Enterobacteriaceae (CPE) represents the most worrisome evolution of the antibiotic resistance crisis, which is almost resistant to most of available antibiotics. This situation is getting even worse particularly due to the recent emergence of colistin resistance. Herein, niclosamide, an FDA-approved traditional drug, and its novel O-alkylamino-tethered derivatives were discovered as new and potent antibacterial agents against carbapenemase-producing and/or colistin resistant Enterobacteriaceae isolates. Among these molecules, compound 10 (HJC0431) with 4-aminobutyl moiety showed the broad antibacterial activities, effective against 6 strains. In vitro checkerboard and time-kill course studies demonstrated the synergistic effects of the screened compounds with colistin against the corresponding strains with various degrees.
• US9562002B2
  申请人：——

  公开号：US9562002B2

  公开（公告）日：2017-02-07